A new trading day began on Friday, with Ovid Therapeutics Inc (NASDAQ: OVID) stock price up 7.63% from the previous day of trading, before settling in for the closing price of $0.96. OVID’s price has ranged from $0.24 to $1.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 24.72% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -38.22%. With a float of $59.51 million, this company’s outstanding shares have now reached $71.11 million.
Ovid Therapeutics Inc (OVID) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ovid Therapeutics Inc is 16.32%, while institutional ownership is 34.63%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.2 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.22% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Here are Ovid Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Let’s dig in a bit further. During the last 5-days, its volume was 1.09 million. That was better than the volume of 0.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.92%.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 93.33%, which indicates a significant increase from 90.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0949 in the past 14 days, which was higher than the 0.0458 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5170, while its 200-day Moving Average is $0.6084. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.0975. Second resistance stands at $1.1651. The third major resistance level sits at $1.2438. If the price goes on to break the first support level at $0.9512, it is likely to go to the next support level at $0.8725. The third support level lies at $0.8049 if the price breaches the second support level.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
With a market capitalization of 73.24 million, the company has a total of 71,110K Shares Outstanding. Currently, annual sales are 570 K while annual income is -26,430 K. The company’s previous quarter sales were 6,270 K while its latest quarter income was -4,680 K.
